← SynDRA
CARIPRAZINE
SynDRA canonical compound SYN0029178 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | DRD3 |
|---|
| Mechanism of action | Dopamine receptor antagonist |
|---|
| Indication | schizophrenia |
|---|
| Disease area | neurology/psychiatry |
|---|
All known targets
- DRD2
- DRD3
- ADRA1D
- DRD1
- DRD4
- DRD5
- Drd2
- Drd3
- HRH1
- HTR1A
- HTR2A
- HTR2B
Mechanisms of action (all sources)
- Dopamine receptor antagonist
- DRD3 MODULATOR
- DRD2 MODULATOR
- DRD2 PARTIAL AGONIST
- HTR1A PARTIAL AGONIST
- HTR2A ANTAGONIST
Drug classes
- Atypical Antipsychotic
- Antipsychotic Agents
- Central Nervous System Agents
- Central Nervous System Depressants
- Psychotropic Drugs
- Tranquilizing Agents
ATC classes
Cross-references
Synonyms
- cariprazine hydrochloride
- vraylar
- RGH-188
- Cariprazina
- Fri-7000188
- GED-129
- MP-214
- Reagila
- RGH 188
- Cariprazine(RGH188)
- UNII-F6RJL8B278
- F6RJL8B278
- CHEMBL3085826
- 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea
- Cariprazine [USAN:INN]
- MP 214
- Cariprazine (USAN/INN)
- Cariprazine (RGH-188)
- C21H32Cl2N4O
- SCHEMBL184342
- SCHEMBL184343
- GTPL7671
- SCHEMBL7861573
- CHEMBL2028019
- CHEBI:90933
- HSDB 8310
- DTXSID80232867
- KPWSJANDNDDRMB-QAQDUYKDSA-N
- MolPort-039-139-594
- BDBM263449
- BCP14691
- BDBM50443101
- BDBM50382290
- ZINC38309313
- 3526AH
- Kariprazin
- trans-N-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-N’,N’-dimethylurea hydrochloride
- Vraylar®
Reported adverse events
- Akathisia
- Anxiety
- Cataract
- Constipation
- Depression
- Dizziness
- Dyskinesia
- Dysphagia
- Fatigue
- Hypertension
- Hypotension
- Increased appetite
Look up CARIPRAZINE in the interactive SynDRA portal →